{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:00:20Z","timestamp":1792000820433,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cmi.2025.09.014","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:32:34Z","timestamp":1759541554000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Randomized clinical trial to evaluate the longitudinal HIV-1 reservoir and inflammation in treatment-na\u00efve people starting dolutegravir\/lamivudine versus dolutegravir plus tenofovir alafenamide\/emtricitabine"],"prefix":"10.1016","volume":"32","author":[{"given":"Abraham","family":"Saborido-Alconchel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Serna-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Trujillo-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Mu\u00f1oz-Muela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Alvarez-R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Sotomayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Lopez-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Raffo-Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Romero-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mariscal-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Roca-Oporto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gutierrez-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Lopez-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.09.014_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.09.014_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2025.09.014_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.014_bib4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.014_bib5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cmi.2022.02.041","article-title":"Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial","volume":"28","author":"Trujillo-Rodr\u00edguez","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.09.014_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.122.057443","article-title":"Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context","volume":"147","author":"Ntsekhe","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cmi.2025.09.014_bib7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40265-016-0546-7","article-title":"Serious non-AIDS events: therapeutic targets of immune activation and chronic inflammation in HIV infection","volume":"76","author":"Hsu","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2025.09.014_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/v11030200","article-title":"Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART","volume":"11","author":"Zicari","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2025.09.014_bib9","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1073\/pnas.1917876117","article-title":"Defective HIV-1 proviruses produce viral proteins","volume":"117","author":"Imamichi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2025.09.014_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/COH.0000000000000849","article-title":"Persistent HIV-1 transcription during ART: time to reassess its significance?","volume":"19","author":"Fombellida-Lopez","year":"2024","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.cmi.2025.09.014_bib11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/v16050751","article-title":"Chronic HIV transcription, translation, and persistent inflammation","volume":"16","author":"Kilroy","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2025.09.014_bib12","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cmi.2025.09.014_bib13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/QAD.0000000000003201","article-title":"Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression","volume":"36","author":"Fletcher","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2025.09.014_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/hiv.12716","article-title":"Two-drug vs. three-drug combinations for HIV-1: do we have enough data to make the switch?","volume":"20","author":"Moreno","year":"2019","journal-title":"HIV Med"},{"key":"10.1016\/j.cmi.2025.09.014_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637910","article-title":"Dual antiretroviral therapy-all quiet beneath the surface?","volume":"12","author":"van Welzen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.09.014_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.976564","article-title":"Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: a modeling study","volume":"13","author":"Serrano-Villar","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.09.014_bib17","article-title":"Long-term changes of inflammatory biomarkers in individuals on suppressive three-drug or two-drug antiretroviral regimens","volume":"13","author":"Serrano-Villar","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.09.014_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205777","article-title":"Absolute CD4+ T cell count overstate immune recovery assessed by CD4+\/CD8+ ratio in HIV-infected patients on treatment","volume":"13","author":"Milan\u00e9s-Guisado","year":"2018","journal-title":"PLoSOne"},{"key":"10.1016\/j.cmi.2025.09.014_bib19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/v14030524","article-title":"DOLAVI real-life study of dolutegravir plus lamivudine in naive HIV-1 patients (48 weeks)","volume":"14","author":"Hidalgo-Tenorio","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2025.09.014_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/QAI.0000000000003073","article-title":"Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG-based or ATV-based dual therapy","volume":"91","author":"Dragoni","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2025.09.014_bib21","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/infdis\/jiae405","article-title":"In-depth analysis of the HIV reservoir confirms effectiveness and safety of DTG\/3TC in a phase 4 randomized controlled switch trial (RUMBA)","volume":"231","author":"De Scheerder","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.014_bib22","first-page":"461","article-title":"Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy","volume":"28","author":"Lombardi","year":"2020","journal-title":"Infez Med"},{"key":"10.1016\/j.cmi.2025.09.014_bib23","doi-asserted-by":"crossref","first-page":"9966","DOI":"10.1038\/s41467-024-54116-1","article-title":"Rapid biphasic decay of intact and defective HIV DNA reservoir during acute treated HIV disease","volume":"15","author":"Barbehenn","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2025.09.014_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.873408","article-title":"Similar CD4\/CD8 ratio recovery after initiation of dolutegravir plus lamivudine versus dolutegravir or bictegravir-based three-drug regimens in naive adults with HIV","volume":"13","author":"Mart\u00ednez-Sanz","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.09.014_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1423734","article-title":"Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors","volume":"15","author":"Saborido-Alconchel","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.09.014_bib26","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/QAI.0000000000002861","article-title":"Changes in serum inflammatory markers in antiretroviral therapy-naive HIV-infected patients starting dolutegravir\/lamivudine or dolutegravir\/lamivudine\/abacavir","volume":"89","author":"Calza","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2025.09.014_bib27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/infdis\/jiae530","article-title":"Impact of dolutegravir plus lamivudine as first-line antiretroviral treatment on HIV-1 reservoir and inflammatory markers in peripheral blood","volume":"231","author":"Bail\u00f3n","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.014_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006285","article-title":"Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation","volume":"13","author":"Gandhi","year":"2017","journal-title":"PLOS Pathog"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:41:04Z","timestamp":1773924064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25004641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1198743X25004641"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.09.014","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized clinical trial to evaluate the longitudinal HIV-1 reservoir and inflammation in treatment-na\u00efve people starting dolutegravir\/lamivudine versus dolutegravir plus tenofovir alafenamide\/emtricitabine","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}